Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Innovation and Product Development news
(page 31)
28 February 2026
Merck and Eisai: WELIREG and LENVIMA Reduce Disease Progression Risk by 30% in Advanced RCC Trial
Phase 3 trial shows WELIREG plus LENVIMA improves progression-free survival in advanced RCC, with FDA reviewing new drug applications.
27 February 2026
CATL and BMW MOU on Battery Passport and Decarbonization
MOU to run pilots for cross-border Battery Passport data exchange, carbon accounting and Catena‑X standards, aligning tech, policies and EU compliance to boost low‑carbon competitiveness.
27 February 2026
FDA Approves Novo Nordisk's Sogroya for New Pediatric Uses
Sogroya, a once-weekly growth hormone, is now approved for children with ISS, SGA, or NS, offering an alternative to daily injections and expanding treatment options.
27 February 2026
Merck's KEYTRUDA and Padcev Cut Event-Free Survival Risk by 47% and Mortality by 35% in Cisplatin-Eligible Bladder Cancer Patients
KEYTRUDA plus Padcev improves survival and reduces recurrence in muscle-invasive bladder cancer, showing potential as a new standard for cisplatin-eligible patients.
27 February 2026
Merck's KEYTRUDA Plus Paclitaxel Boosts Survival in Platinum-Resistant Ovarian Cancer
KEYTRUDA plus paclitaxel improves overall survival in platinum-resistant ovarian cancer, regardless of PD-L1 status, as shown in the KEYNOTE-B96 trial.
27 February 2026
Air Liquide and Holcim Partner to Decarbonize Belgian Cement Production
The agreement aims to capture 1.1 million tons of CO₂ annually at Holcim's Obourg plant, supporting EU's 2050 net zero target through advanced carbon capture and storage technology.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
26 February 2026
GSK's Bepirovirsen Under Review in Japan for Chronic Hepatitis B Treatment
Japan reviews bepirovirsen for chronic hepatitis B. Phase III trials show higher functional cure rates and acceptable safety. SENKU designation granted for expedited review.
26 February 2026
thyssenkrupp Automotive Body Solutions Joins IPAI for Smart Manufacturing Innovation
The company joins IPAI to integrate AI in manufacturing, enhancing robotics and expanding globally, with a focus on intelligent production and quality monitoring.
26 February 2026
Grupa Azoty Introduces New Sulphur-Containing Fertilizer
The new product strengthens the fertilizer segment, supporting stable growth and competition in Europe while enhancing food security in Poland and the region.
26 February 2026
PureCycle Technologies Q4 2025 Results and Update
Record production, revenue growth, expansion in Thailand and Belgium, and leadership changes. Gen-2 design shows cost efficiency. Financials stable with ongoing projects and debt management.
26 February 2026
Asahi Kasei Acquires Aicuris for €780 Million
The acquisition enhances Asahi Kasei's pharmaceutical platform in severe infectious diseases, leveraging existing infrastructure for growth and expanding its treatment portfolio.
26 February 2026
Johnson & Johnson Reports Positive Early Results for Pasritamig and Docetaxel in Prostate Cancer
Phase 1b study shows pasritamig and docetaxel combo is safe and effective in prostate cancer, with high PSA response rates, supporting Phase 3 trials.
26 February 2026
BASF Introduces Biomass Balance Autofroth Foam for North American Market
BMB Autofroth foam cuts carbon emissions by 18-20%, offers a drop-in solution for sustainability without process changes, and suits various applications.
26 February 2026
Lilly's Orforglipron Outperforms Semaglutide in Diabetes Trial
Orforglipron 36 mg reduced A1C by 2.2% and weight by 9.2%, surpassing semaglutide in a 52-week trial with 1,698 participants. Results published in The Lancet.
26 February 2026
Boehringer Ingelheim Licenses Immune Disease Program from Sitryx
Boehringer gains exclusive rights to Sitryx's preclinical program for autoimmune diseases, with potential payments over $500M and tiered royalties on future sales.
26 February 2026
Veolia Expands in India with Major Mumbai Water Projects
Secures 15-year contracts for Mumbai's largest water plants, enhancing water security and efficiency with advanced tech, aiming to double India's revenues by 2030.
26 February 2026
Eni Reports Strong 2025 Financial and Strategic Progress
Strong Q4 results with 35% net income growth. Major projects launched, production up 7%. LNG expansion, biofuels growth, and strategic partnerships enhance resilience and shareholder returns.
26 February 2026
Clariant Achieves Third Year of EBITDA Margin Growth
Q4 2025 sales rose 1% in local currencies. FY 2025 EBITDA margin up 180 basis points to 17.8%. Performance programs saved CHF 50M. 2026 sales expected flat; EBITDA margin around 18%.
26 February 2026
Technip Energies 2025 Financial Results
Strong 2025 results with revenue and EBITDA growth, dividend increase, share buyback, and strategic acquisition. Positive outlook for 2026 with robust backlog and sustainability focus.
26 February 2026
2025 Results: Arkema Performance Summary
Strong cash flow and EBITDA, sales growth in key markets, successful capacity expansions, and sustainability progress. Dividend stable; 2026 targets slight EBITDA growth amid weak demand.
25 February 2026
ViiV Healthcare: Lotivibart Shows 94% Viral Suppression in Long-Acting HIV Treatment
Lotivibart, combined with CAB LA, maintained viral suppression in 94% of participants. Study progresses to test twice-yearly dosing. Well-tolerated with fewer adverse events in IV group.
25 February 2026
ViiV Healthcare Unveils Data on Twice-Yearly HIV Treatments
VH184 and VH499 show promise for twice-yearly HIV treatment, with improved resistance and tolerability, reducing the need for daily medication.
25 February 2026
Merck Animal Health's NUMELVI: FDA-Approved JAK Inhibitor for Canine Allergic Dermatitis
FDA approves NUMELVI for dogs 6+ months, a JAK inhibitor for allergic dermatitis, offering rapid itch relief and easy dosing. Available spring 2026.
25 February 2026
Merck Presents Phase 3 Trial Results for HIV-1 Treatment DOR/ISL at CROI 2026
DOR/ISL shows non-inferiority and similar safety to BIC/FTC/TAF in HIV-1 treatment-naïve adults and maintains suppression in those switching from other therapies.
25 February 2026
Novo Nordisk and Vivtex Collaborate on Oral Medicines for Obesity and Diabetes
The partnership aims to develop oral biologics for obesity and diabetes, leveraging Vivtex's technology for better bioavailability and Novo Nordisk's expertise in global development and commercialization.
25 February 2026
Renault's Ampere and Basquevolt Partner on Next-Gen Lithium-Metal Batteries
The partnership aims to advance lithium metal batteries for EVs, enhancing energy density, thermal stability, and cost efficiency, while reducing manufacturing complexity and investment.
25 February 2026
Regulation Essential for OCCS Investment in Maritime Decarbonization
A DNV report highlights the need for clear regulations to advance OCCS technology, crucial for maritime decarbonization, with pilot projects showing technical feasibility and economic potential.
25 February 2026
Eni Confirms Biorefining Investment in Sannazzaro de’ Burgondi
Eni plans to convert Sannazzaro refinery units to biorefinery, boosting biofuel output without affecting traditional fuel production, aiming for 550,000 tonnes/year by 2028.
25 February 2026
Siemens and CAPHENIA Partner to Scale Sustainable Aviation Fuel
The partnership aims to scale SAF production using CAPHENIA's plasma technology, enhancing efficiency and enabling global rollout with Siemens' digitalization and automation solutions.
25 February 2026
Asahi Kasei Pharma Secures Global License with Alchemedicine for Novel Compounds
The agreement grants exclusive rights to develop preclinical compounds for autoimmune diseases, marking a deepened partnership and strategic alignment.
← Previous
Next →
